Approach to the patient with type 2 diabetes and progressive kidney disease

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 7, 2010, Pages 3103-3110

  Seaquist, Elizabeth R ^a   Ibrahim, Hassan N ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CALCITRIOL; CALCIUM; CHOLESTEROL; CREATININE; DILTIAZEM; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; INSULIN GLARGINE; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PARATHYROID HORMONE; TRIACYLGLYCEROL; VITAMIN D;

AGED; ALBUMINURIA; ANEMIA; ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE; BODY MASS; CALCIUM BLOOD LEVEL; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DIABETIC FOOT; DIABETIC MACULAR EDEMA; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEART RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTRAOCULAR HEMORRHAGE; KIDNEY FAILURE; LASER COAGULATION; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PARATHYROID HORMONE BLOOD LEVEL; PARESTHESIA; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; RETINA EXAMINATION; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN BLOOD LEVEL; WALKING; CHRONIC KIDNEY FAILURE; DISEASE COURSE; KIDNEY TRANSPLANTATION; MIDDLE AGED; PROGNOSIS; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

AGED; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MIDDLE AGED; PROGNOSIS; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 77954916374     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-0504     Document Type: Article

References (35)

1. Jones CA, Krolewski AS, Rogus J, Xue JL, Collins A, Warram JH 2005 Epidemic of end-stage renal disease in people with diabetes in the United States population: do we know the cause? Kidney Int 67:1684-1691
2. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F 2008 Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560-2572
3. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR 2000 Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Brit Med J 321:405-412
4. Mogensen CE 1984 Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310:356-360
5. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR, Grp US 2006 Risk factors for renal dysfunction in type 2 diabetes - UK Prospective Diabetes Study 74. Diabetes 55:1832-1839 (Pubitemid 44324140)
6. Rossing P 2006 Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005. Diabetologia 49:11-19
7. Thomaseth K, Pacini G, Morelli P, Tonolo G, Nosadini R 2008 Importance of glycemic control on the course of glomerular filtration rate in type 2 diabetes with hypertension and microalbuminuria under tight blood pressure control. Nutr Metab Cardiovasc Dis 18:632-638
8. Shamoon H, Duffy H, Fleischer N, Engel S, Saenger P, Strelzyn M, Litwak M, Wylierosett J, Farkash A, Geiger D, Engel H, Fleischman J, Pompi D, Ginsberg N, Glover M, Brisman M, Walker E, Thomashunis A, Gonzalez J, Genuth S, Brown E, Dahms W, Pugsley P, Mayer L, Kerr D, Landau B, Singerman L, Rice T, Novak M, Smithbrewer S, McConnell J, Drotar D, Woods D, Katirgi B, Litvene M, Brown C, Lusk M, Campbell R, et al. 1993 The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes-mellitus. N Engl J Med 329:977-986
9. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD, Investigators V 2009 Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129-139
10. Gerstein HC, Miller ME, Byington RP, Goff Jr DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm Jr RH, Probstfield JL, Simons-Morton DG, Friedewald WT 2008 Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545-2559 (Pubitemid 351831356)
11. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE 2003 Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus - systematic review and meta-analysis. Arch Intern Med 163:2594-2602 (Pubitemid 37464417)
12. Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR 2008 Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care 31:2086-2091
13. Snyder RW, Berns JS 2004 Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial 17:365-370
14. Linnebjerg H, Kothare PA, Park S, Mace K, Reddy S, Mitchell M, Lins R 2007 Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 64:317-327 (Pubitemid 47283860)
15. Bergman AJ, Cote J, Yi B, Marbury T, Swan SK, Smith W, Gottesdiener K, Wagner J, Herman GA 2007 Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 30:1862-1864 (Pubitemid 47036366)
16. Czock D, Aisenpreis U, Rasche FM, Jehle PM 2003 Pharmacokinetics and pharmacodynamics of lispro-insulin in hemodialysis patients with diabetes mellitus. Int J Clin Pharmacol Ther 41:492-497 (Pubitemid 37258869)
17. Hopkins K, Bakris GL 2009 Hypertension goals in advanced stage kidney disease. Clin J Am Soc Nephrol 4:S92-S94
18. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C 2008 Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547-1559 (Pubitemid 351522739)
19. Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD 2009 Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 20:2641-2650
20. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK: AVOID Study Investigators 2008 Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358:2433-2446
21. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M 1998 Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234 (Pubitemid 28350165)
22. Sacks FM, Tonkin AM, Craven T, Pfeffer MA, Shepherd J, Keech A, Furberg CD, Braunwald E 2002 Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation 105:1424-1428 (Pubitemid 34263272)
23. Collins R, Armitage J, Parish S, Sleigh P, Peto R 2003 MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005-2016
24. Krolewski AS, Warram JH, Christlieb AR 1994 Hypercholesterolemia - a determinant of renal-function loss and deaths in IDDM patients with nephropathy. Kidney Int Suppl 45:S125-S131
25. Tonolo G, Velussi M, Brocco E, Abaterusso C, Carraro A, Morgia G, Satta A, Faedda R, Abhyankar A, Luthman H, Nosadini R 2006 Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes. Kidney Int 70:177-186 (Pubitemid 44000136)
26. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E 2005 Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238-248 (Pubitemid 41058323)
27. Courtney AE, Maxwell AP 2008 Critiques of Clinical Guidelines in Nephrology: Anaemia. Nephron Clinical Practice 110:C115-C125
28. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R 2009 A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:2019-2032
29. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M 2008 Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359:584-592
30. Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Ishani A, Kasiske B, Liu J, Mau LW, McBean M, Murray A, St Peter W, Guo H, Li Q, Li S, Li S, Peng Y, Qiu Y, Roberts T, Skeans M, Snyder J, Solid C, Wang C, Weinhandl E, Zaun D, Arko C, Chen SC, Dalleska F, Daniels F, Dunning S, Ebben J, Frazier E, Hanzlik C, Johnson R, Sheets D, Wang X, Forrest B, Constantini E, Everson S, Eggers P, Agodoa L 2009 United States renal data system 2008 annual data report. Am J Kidney Dis 53(1 Suppl):S1-S379
31. Abecassis M, Bartlett ST, Collins AJ, Davis CL, Delmonico FL, Friedewald JJ, Hays R, Howard A, Jones E, Leichtman AB, Merion RM, Metzger RA, Pradel F, Schweitzer EJ, Velez RL, Gaston RS 2008 Kidney transplantation as primary therapy for end-stage renal disease: a National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQI (TM)) conference. Clin J Am Soc Nephrol 3:471-480
32. McCullough KP, Keith DS, Meyer KH, Stock PG, Brayman KL, Leichtman AB 2009 Kidney and pancreas transplantation in the United States, 1998-2007: access for patients with diabetes and end-stage renal disease. Am J Transplant 9:894-906
33. Leichtman AB, Cohen D, Keith D, O'Connor K, Goldstein M, McBride V, Gould CJ, Christensen LL, Ashby VB 2008 Kidney and pancreas transplantation in the United States, 1997-2006: the HRSA breakthrough collaboratives and the 58 DSA challenge. Am J Transplant 8:946-957 (Pubitemid 351389063)
34. Turner RC, Cull CA, Stratton IM, Manley SE, Kohner EM, Matthews DR, Neil HAW, Levy JC, Holman RR 1995 UK Prospective Diabetes Study 16 - overview of 6 years therapy of type-II diabetes, a progressive disease. Diabetes 44:1249-1258
35. de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM 2009 Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 20:2075-2084